Windtree Therapeutics Inc. [WINT] fell -80.04% so far this year. What now?

0


Windtree Therapeutics Inc. [NASDAQ: WINT] The stock went on an upward trajectory, up more than 2.46% on Wednesday, which represents a one-week price increase of more than 3.09%. Company report on September 28, 2022 Windtree Therapeutics announces a positive phase 2 Istaroxime study in early cardiogenic shock (SEISMiC) published in the European Journal of Heart Failure.


Top 5 cheap stocks to own right now

While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.

Register here to get a free report now. .

sponsored by


Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on developing multiple interventions in the late stages of acute cardiovascular disorders, today announced that positive results from a phase II study of istaroxime in early cardiogenic shock have been published in the European Journal. Heart failure (https://doi.org/10.1002/ejhf.2629). Cardiogenic shock is caused by heart failure which results in decreased cardiac output from the body and is characterized by very low blood pressure and decreased blood flow to the peripheral organs. It requires urgent treatment and has a high rate of morbidity and mortality. Windtree conducted a study called SEISMiC of istaroxime in patients with early cardiogenic shock due to heart failure.

“Results published in the European Journal of Heart Failure demonstrate that estaroxime can rapidly and significantly improve blood pressure and key parameters of cardiac function in a failing heart with an acceptable tolerance profile in our studies to date,” said Dr. Medical Officer at Windtree. The positive results of the SEISMiC study are consistent with previous phase II studies in acute heart failure and help establish and promote the rationale for estaroxime as a potential treatment for cardiogenic shock. We look forward to the next steps of the istaroxime development program in which we plan to expand and improve the dosing regimen with a small number of early-cardio shock patients and meet with the Food and Drug Administration to discuss a potential Phase 3 program.”

Over the past 12 months, WINT stock is down -82.69%. Windtree Therapeutics Inc stock’s 1-year outlook is for a potential rise of 89.33. WINT stock currently has an average equity rating of 1.00, and is trading near a bullish pattern in the stock market.

The stock has a market capitalization of $9.86 million, with 29.20 million shares outstanding and 21.68 million shares in current float. Compared to an average trading volume of 1.41 million shares, WINT stock reached a trading volume of 2,926385 on the last trading day, which is why market watchers consider the stock to be active.

Educator’s opinion of Windtree Therapeutics Inc. [WINT]:

Based on careful and fact-backed analysis by Wall Street experts, the current consensus on a price target for WINT stock is $3.00 per share. Target price analysis and stock performance are usually carefully studied by market experts, and the current Wall Street consensus on WINT stock is a set recommendation at 1.00. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 represents hold, and 2 indicates buy.

Ladenburg Thalmann made an appreciation for the stock of Windtree Therapeutics Inc. , retaining their opinion of the stock as Buy, with their previous recommendation back on June 26, 2020.

The Average True Range (ATR) is set by Windtree Therapeutics Inc. at 0.05 and the price-to-book ratio for the last quarter was 0.49, with the price-to-cash ratio for the stock in the same quarter set at 0.37.

WINT stock performance analysis:

Windtree Therapeutics Inc. [WINT] Gain in the green at the end of last week, gains in positive trend and gains of 3.09. With this latest performance, WINT shares are down -21.32% over the past four-week period, as well as down -70.88% over the past six months – not to mention a -82.69% drop in the last year of trading.

Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for WINT stock for the past two weeks was set at 39.98, with the RSI for the last one trading at 38.12, and the three-week RSI set at 41.54 for Windtree Therapeutics Inc. [WINT]. The current moving average for the last 50 trading days for this stock is 0.3925 while it recorded at 0.3083 for the last trading week, and 0.7965 for the last 200 days.

An insight into the fundamentals of Windtree Therapeutics Inc.:

The return on equity for this stock fell to -121.39, with the return on assets remaining at -72.08.

The liquidity data of Windtree Therapeutics Inc. Interesting too, with the quick ratio at 2.50 and the current ratio at 2.50.

Windtree Therapeutics Inc. [WINT] Insider position details

Currently, about $1 million, or 5.10% of WINT’s stock, is in the hands of institutional investors. The three largest institutional owners of WINT shares are: VANGUARD GROUP INC with 583,853 ownership, which is approximately 5.91% of the company’s market capitalization and approximately 2.00% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, which owns 361,395 shares of stock with an approximate value of $0.12 million in WINT stock; and GEODE CAPITAL MANAGEMENT, LLC, with $51000.0 in WINT stock with ownership of approximately 0% of the company’s market capitalization.

Positions increased in shares of Windtree Therapeutics Inc. held by institutional investors at the end of August and at the time of the August report, as 10 institutional owners consolidated their position in Windtree Therapeutics Inc. [NASDAQ:WINT] About 297,878 shares. In addition, the number of 7 investors decreased positions by about 249,342 shares, while 10 investors held positions by 1,020,495 shares. The said changes put institutional holdings at 1,567,715 shares, according to the latest report from the Securities and Exchange Commission. WINT 2 had new institutional investment totaling 19,373 shares, while 4 institutional investors sold positions worth 215,011 shares during the same period.

Leave A Reply

Your email address will not be published.